Press Release: New Study Finds that Antimicrobial Resistance (AMR) could cost the U.S. $655 billion by 2045. Study finds: - Annual costs to treat AMR are projected to rise from $31B per year in 2025 to $52B by 2045. - AMR-associated hospital bed utilization is projected to increase 68% by 2045, from approximately 2.1 million additional U.S. bed-days annually to 3.5 million. - Resistant infections were associated with four additional hospital days and $21,453 in additional costs per infection, after adjusting for patients’ pre-existing health conditions. Read the full press release and research here: vitaltransformation.com/2026…

Duane Schulthess (@DuaneSchulthess) speaks today at IDWeek 2026! Join Vital Transformation’s oral presentation on antimicrobial resistance, hospital costs, and bed displacement at 3:30 p.m. Eastern in Room 209 ABC. IDWeek 2026 | October 23, 2026 | 3:30 - 3:45 p.m. Eastern Walter E. Washington Convention Center · Room 209 ABC #VitalTransformation #IDWeek2026 #AMR @IDWeekmtg

In our latest Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) speaks with Eric Lindquist about the decline in biotech venture funding. Eric describes more companies seeking funding than venture capital firms with money to deploy, making investors more selective. He also explains how mandates to invest in European or U.S. companies narrow fundraising options. Watch the full podcast on Vital Transformation's YouTube. #VitalHealthPodcast #Biotech #VentureCapital #BiotechInvestment

When European and U.S. medicine prices are set separately, a company can accept a lower European price to generate revenue from another market while preserving its higher U.S. margins. Most Favored Nation (MFN) reference pricing could change that by using the lower European price to set the U.S. price. For companies that earn most of their profits in the U.S., the additional European sales may not offset the reduction in profits across their U.S. business, giving them a reason to delay or reconsider a European launch. In our latest Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) speaks with Eric Lindquist about Most Favored Nation (MFN) and the need for consistent policy. #VitalHealthPodcast #MFN #DrugPricing #MarketAccess

In our latest Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) and Harry Bowen explain how Most Favored Nation (MFN) pricing could change a company's decision to launch a medicine in Europe. A lower negotiated European price could become the reference for its U.S. price. Harry Bowen argues that protecting U.S. profits could then outweigh the benefit of additional European sales, giving companies an incentive to withhold launches in lower-priced markets. #VitalHealthPodcast #MFN #DrugPricing #MarketAccess

A promising drug can have market potential and still not fit a company's current commercial team or portfolio. Eric Lindquist explains that Pfizer made this assessment of gedatolisib (Revtorpyk) and could still benefit from the drug's success through royalties and milestones. In our latest Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) speaks with Eric about why a large company would license out a potentially profitable drug and how the Inflation Reduction Act (IRA) has affected the deal. #VitalHealthPodcast #DrugDevelopment #Biopharma #DrugLicensing

One week until Duane Schulthess (@DuaneSchulthess) presents at IDWeek 2026! Our presentation examines antimicrobial resistance (AMR), hospital costs, and bed displacement across three major infections in the United States. IDWeek 2026 October 23, 2026 | 3:30 - 3:45 p.m. Eastern Walter E. Washington Convention Center · Room 209 ABC #VitalTransformation #IDWeek2026 #AMR @IDWeekmtg

In our recent Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) and Harry Bowen discuss how U.S. policy can influence biotech investment in Europe. They examine the incentive for companies to bring corporate profits held overseas back to the U.S. following the Tax Cuts and Jobs Act, and consider how that movement of capital may have affected funding for European biotech. #VitalHealthPodcast #BiotechInvestment #HealthPolicy

European medicine-pricing policy is the starting point for a U.S. innovation question. At EIRA Conference 2026, Duane Schulthess (@DuaneSchulthess) will present “Effects of European Price Control on U.S. Pharmaceutical Innovation.” #VitalTransformation #EiraConference2026 #InnovationPolicy @EiraInitiative

In our recent Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) and Harry Bowen revisit the reasoning behind centralized approvals in Europe as part of their wider discussion of price controls and innovation. Duane will present on European price controls and U.S. pharmaceutical innovation at the EIRA Conference in Paris. His session is on October 29th, - CET, at Maison de l'Amérique Latine. #VitalHealthPodcast #DrugDevelopment #HealthPolicy #EIRAConference2026 @EiraInitiative

Vital Transformation will participate in the EIRA Conference 2026, taking place October 29 - 30 in Paris. Duane Schulthess speaks in Panel 4 on October 29, examining European price controls and U.S. pharmaceutical innovation. - Event Details: eirainitiative.org/events/ - Register: docs.google.com/forms/d/e/1F… #VitalTransformation #EiraConference2026 #InnovationPolicy

In this episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Eric Lindquist, biotech entrepreneur and former Chief Business and Commercial Officer at Celcuity, about the 2021 deal to license gedatolisib from Pfizer. Drawing on Lindquist’s experience with the transaction, they explore portfolio fit, the responsibilities of advancing a medicine, and how funding, pricing policy, and international competition shape drug development and patient access. Watch the episode here: youtu.be/yA9OR264zO4 #VitalHealthPodcast #Biotech #DrugDevelopment

Competing for the Cure brings the policy environment for biopharmaceutical innovation into focus. Vital Transformation will participate in EIRA Conference 2026 (@EiraInitiative), taking place October 29 - 30 in Paris. Duane Schulthess (@DuaneSchulthess) speaks in Panel 4 on October 29, examining European price controls and U.S. pharmaceutical innovation. EIRA Conference 2026 · Panel 4 October 29, 2026 | 15:15 - 16:45 CET Maison de l’Amérique latine · Paris Event Details: eirainitiative.org/events/ Register: docs.google.com/forms/d/e/1F… #VitalTransformation #EiraConference2026 #InnovationPolicy

Drug development depends on investors being willing to fund the path from research to market. When expected revenues are lower, late-stage projects can become less attractive to finance. For Europe, this raises questions about how pricing policy affects the funding available to turn research into medicines for patients. In this episode of the Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) and Harry Bowen examine Europe's early- and late-stage venture capital funding relative to the U.S. and discuss what those historical trends could mean for investment and research infrastructure. Watch the full episode here: youtu.be/UPOXhVXrU8w #VitalHealthPodcast #Biopharma #VentureCapital #HealthPolicy

Most Favored Nation (MFN) pricing ties U.S. medicine prices to lower prices in selected foreign markets. If a lower price abroad also reduces revenue in the U.S., companies may become less willing to accept that price or to introduce a medicine in that market at all. That could turn a pricing policy into an access problem for patients. In this episode of the Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) and Harry P. Bowen discuss how MFN could change pricing negotiations, launch decisions, and the availability of new medicines. Watch the full episode here: youtu.be/UPOXhVXrU8w #VitalHealthPodcast #MFN #DrugPricing #MarketAccess

What can Europe's experience with price controls tell us about the debate over most-favored-nation (MFN) drug pricing? In our latest Vital Health Podcast, Duane Schulthess (@DuaneSchulthess) and Harry Bowen examine how pricing rules can influence where medicines launch, how investors assess future returns, and where pharmaceutical research takes place. The conversation looks beyond the price itself to the incentives, uncertainty, and policy trade-offs that shape innovation. Watch the full episode: youtu.be/UPOXhVXrU8w #VitalHealthPodcast #IRA #MFN #DrugPricing #Biopharma #Innovation

Japan, Europe, and the United States use different approaches to medicine pricing. What questions should we ask when comparing their innovation environments? EIRA’s Panel 4, where Duane Schulthess will be speaking, includes a comparative discussion of price-control regimes alongside presentations on European policy and intellectual property rights. The session offers a chance to consider these topics together. - Event Details: eirainitiative.org/events/ - Register: docs.google.com/forms/d/e/1F… #VitalTransformation #EiraConference2026 #InnovationPolicy @DuaneSchulthess

What does antimicrobial resistance (AMR) mean for the use of hospital beds? Bed displacement is one topic in our upcoming IDWeek presentation, where Duane Schulthess will speak. The session will consider this dimension alongside hospital costs across three major infections. IDWeek 2026 · VT's Presentation October 23, 2026 | 3:30 - 3:45 p.m. Eastern Walter E. Washington Convention Center · Room 209 ABC Event Details: idweek2026.eventscribe.net/a… Register: idweek.org/registration/ #VitalTransformation #IDWeek2026 #AMR @DuaneSchulthess @VitalTransform @IDWeekmtg

One month away: @DuaneSchulthess speaks at EIRA in Paris on October 29th. European price controls and U.S. pharmaceutical innovation. Panel 4, 15:15 - 16:45 CET. - Event Details: eirainitiative.org/events/ - Register: docs.google.com/forms/d/e/1F… #VitalTransformation #EiraConference2026 #InnovationPolicy @EiraInitiative